SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Binymin K, Cooper RG. Late reactivation of spinal tuberculosis by low-dose methotrexate therapy in a patient with rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 3412.
  • 2
    Hernandez-Cruz B, Sifuentes-Osornio J, Ponce-de-Leon RS, Ponce-de-Leon GA, Diaz-Jouanen E. Mycobacterium tuberculosis infection in patients with systemic rheumatic diseases: a case-series. Clin Exp Rheumatol 1999; 17: 28996.
  • 3
    Hernandez-Cruz B, Ponce-de-Leon-Rosales S, Sifuentes-Osornio J, Ponce-de-Leon-Garduno A, Diaz-Jouanen E. Tuberculosis prophylaxis in patients with steroid treatment and systemic rheumatic diseases: a case-control study. Clin Exp Rheumatol 1999; 17: 817.
  • 4
    Kogure T, Fujinaga H, Niizawa A, Shimada Y, Itoh T, Ochiai H, et al. Rheumatoid arthritis complicated by mycobacterium tuberculosis: are there characteristics predisposing to this association? J Clin Rheumatol 1999; 5: 1721.
  • 5
    Di Girolamo C, Pappone N, Melillo E, Rengo C, Giuliano F, Melillo G. Cavitary lung tuberculosis in a rheumatoid arthritis patient treated with low-dose methotrexate and steroid pulse therapy. Br J Rheumatol 1998; 37: 11367.
  • 6
    Uthman I, Bizri AR, Hajj AR, Haraoui B. Miliary tuberculosis presenting as tenosynovitis in a case of rheumatoid arthritis. J Infect 1998; 37: 1968.
  • 7
    Haas C, Youinou P. [ Tuberculosis and rheumatoid arthritis: apropos of 4 cases]. Ann Med Interne (Paris) 1996; 147: 3757. French.
  • 8
    Miyazawa H, Suzuki K, Yamagishi F, Sasaki Y, Sugito K, Ihara S. [ A case of miliary tuberculosis after adrenocorticosteroid medication for tuberculosis of the wrist]. Kekkaku 1994; 69: 159. Japanese.
  • 9
    McCarty DJ. Personal experience in the treatment of seropositive rheumatoid arthritis with drugs used in combination. Semin Arthritis Rheum 1993; 23 Suppl 1: 429.
  • 10
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098104.
  • 11
    Kessler DA. Introducing MEDWatch: a new approach to reporting medication and device adverse effects and product problems. JAMA 1993; 269: 27658.
  • 12
    Centers for Disease Control and Prevention (CDC). Reported tuberculosis in the United States, 2000. Atlanta (GA): US Department of Health and Human Services, CDC; August 2001.
  • 13
    Centers for Disease Control and Prevention (CDC). Reported tuberculosis in the United States, 1999. Atlanta (GA): US Department of Health and Human Services, CDC; August 2000.
  • 14
    Wolfe F, Flowers N, Anderson J, Urbansky K. Tuberculosis rates are not increased in rheumatoid arthritis [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S105.
  • 15
    Wolfe F, Flowers N, Anderson J. The National Rheumatic Disease Data Bank: case mix and severity characteristics of patients in rheumatological practice [abstract]. Arthritis Rheum 1998; 41 Suppl 9: S132.
  • 16
    Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003; 30: 3640.
  • 17
    Wolfe F, Anderson J, Burke TA, Arguelles LM, Pettitt D. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J Rheumatol 2002; 29: 46773.
  • 18
    Wolfe F, Flowers N, Burke TA, Arguelles LM, Pettitt D. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 2002; 29: 101522.
  • 19
    Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982; 9: 78993.
  • 20
    Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 13745.
  • 21
    Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996; 23: 140717.
  • 22
    Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 47383.
  • 23
    Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997; 36: 5519.
  • 24
    Wolfe F, Hawley DJ. Measurement of the quality of life in rheumatic disorders using the EuroQol. Br J Rheumatol 1997; 36: 78693.
  • 25
    US Bureau of the Census. White population by Hispanic or Latino origin. Washington (DC): US Bureau of the Census; 2000. Table 4.
  • 26
    Bailey TC, Fraser VJ, Spitznagel EL, Dunagan WC. Risk factors for a positive tuberculin skin test among employees of an urban, midwestern teaching hospital. Ann Intern Med 1995; 122: 5805.
  • 27
    Weinick RM, Zuvekas SH, Cohen JW. Racial and ethnic differences in access to and use of health care services, 1977 to 1996. Med Care Res Rev 2000; 57 Suppl 1: 3654.
  • 28
    Mukamel DB, Murthy AS, Weimer DL. Racial differences in access to high-quality cardiac surgeons. Am J Public Health 2000; 90: 17747.
  • 29
    Moinpour CM, Atkinson JO, Thomas SM, Underwood SM, Harvey C, Parzuchowski J, et al. Minority recruitment in the prostate cancer prevention trial. Ann Epidemiol 2000; 10 Suppl 8: S85S91.
  • 30
    Becker G. Effects of being uninsured on ethnic minorities' management of chronic illness. West J Med 2001; 175: 1923.
  • 31
    Cottler LB, Zipp JF, Robins LN, Spitznagel EL. Difficult-to-recruit respondents and their effect on prevalence estimates in an epidemiologic survey. Am J Epidemiol 1987; 125: 32939.
  • 32
    Jackson R, Chambless LE, Yang K, Byrne T, Watson R, Folsom A, et al, for the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Differences between respondents and nonrespondents in a multicenter community-based study vary by gender ethnicity. J Clin Epidemiol 1996; 49: 14416.
  • 33
    Vernon SW, Roberts RE, Lee ES. Ethnic status and participation in longitudinal health surveys. Am J Epidemiol 1984; 119: 99113.
  • 34
    Holt VL, Martin DP, LoGerfo JP. Correlates and effect of non-response in a postpartum survey of obstetrical care quality. J Clin Epidemiol 1997; 50: 111722.
  • 35
    Salmon-Ceron D. Recommendations for the prevention and management of tuberculosis in patients taking infliximab. Ann Med Interne (Paris) 2002; 153: 42931.
  • 36
    Furst DE, Cush J, Kaufmann S, Siegel J, Kurth R. Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis 2002; 61 Suppl 2: ii62ii63.
  • 37
    Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 14855.
  • 38
    Scallon BJ, Trinh H, Nedelman M, Brennan FM, Feldmann M, Ghrayeb J. Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins. Cytokine 1995; 7: 75970.
  • 39
    Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121: 114557.
  • 40
    Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7: 2519.
  • 41
    Lucas R, Tacchini-Cottier F, Guler R, Vesin D, Jemelin S, Olleros ML, et al. A role for lymphotoxin beta receptor in host defense against Mycobacterium bovis BCG infection. Eur J Immunol 1999; 29: 400210.